As per MRFR analysis, the US Cardiopulmonary Exercise Testing Market Size was estimated at 220.5 (USD Million) in 2023.The US Cardiopulmonary Exercise Testing Market Industry is expected to grow from 235.2(USD Million) in 2024 to 530 (USD Million) by 2035. The US Cardiopulmonary Exercise Testing Market CAGR (growth rate) is expected to be around 7.665% during the forecast period (2025 - 2035)
The US Cardiopulmonary Exercise Testing Market is experiencing notable market trends driven by an increasing awareness of the importance of cardiovascular health and the rising prevalence of chronic diseases. Cardiopulmonary exercise testing (CPET) is becoming essential in the diagnosis and management of conditions such as heart failure, chronic obstructive pulmonary disease, and other respiratory diseases. This growing recognition of CPET's role in clinical practice is prompting healthcare providers to adopt these tests more widely. Additionally, advancements in technology are allowing for more accurate and efficient testing procedures, making CPET more accessible to a broad range of patients.
Opportunities to be explored include the integration of telemedicine and remote monitoring with CPET. As telehealth continues to grow in the US, healthcare facilities can enhance patient engagement and streamline the testing process, leading to better patient outcomes. Furthermore, there is potential for the introduction of new devices and protocols specifically designed for at-home testing, making CPET available to patients who may have difficulty accessing traditional healthcare settings. Trends in recent times indicate an increase in research conducted on the role of exercise testing in various therapeutic and rehabilitation settings. Emphasis is being placed on developing personalized medicine approaches that tailor exercise prescriptions based on individual patient profiles.
This focus aligns with the US healthcare system's shift towards value-based care, where outcomes are prioritized over the volume of services provided. With the growing emphasis on preventive care, facilities offering cardiopulmonary exercise testing may find themselves in a favorable position as healthcare systems seek to detect health issues early and improve overall population health.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The rising prevalence of respiratory and cardiovascular disorders in the United States is accelerating the expansion of the US Cardiopulmonary Exercise Testing Market Industry. According to the Centers for Disease Control and Prevention (CDC), cardiovascular illnesses cause roughly 697,000 fatalities in the United States each year, accounting for one out of every five deaths. Chronic respiratory disorders are also on the rise, with the American Lung Association noting an increase in ailments, including chronic obstructive pulmonary disease (COPD) and asthma, which impact millions of people.
This increase in disease incidence needs more thorough cardiac evaluations and exercise testing in clinical settings, creating a greater demand for improved cardiopulmonary testing procedures. National healthcare agencies, such as the National Heart, Lung, and Blood Institute, push for routine cardiovascular preventive testing, persuading hospitals to include these tests for improved patient outcomes.
Technological innovations within the US Cardiopulmonary Exercise Testing Market Industry are enhancing the accuracy and efficiency of testing procedures. Equipment providers are increasingly integrating sophisticated data analytics, real-time monitoring systems, and artificial intelligence functionalities into exercise testing systems. FDA approvals for newer, more advanced devices, such as portable spirometers and updated metabolic carts, are becoming more common.
As per the FDA database, over 25 new technologies related to pulmonary and cardiovascular testing devices have been cleared since 2020 alone. This wave of innovation not only improves the testing experience but also promotes the broad adoption of exercise testing both in clinical and home settings.
The increased focus on preventive healthcare is translating into a greater demand for cardiopulmonary exercise testing in the United States. The US government and various health organizations are emphasizing the importance of preventive measures, which can significantly decrease healthcare costs associated with advanced diseases. According to the Office of Disease Prevention and Health Promotion, health promotion and preventive services help save approximately $2.10 for every dollar spent.
As more healthcare providers aim to adopt preventive testing modalities, the US Cardiopulmonary Exercise Testing Market Industry stands poised for growth, particularly as fitness and wellness trends encourage individuals to participate in regular health assessments with a focus on cardiovascular health.
The Product segment of the US Cardiopulmonary Exercise Testing Market is intricate and diverse, showcasing various technologies and solutions that cater to the growing demand for effective cardiopulmonary diagnostics and monitoring. Among these, CPET Metabolic Carts play a pivotal role as they are essential for comprehensive metabolic assessment during exercise testing. These carts provide critical insights into an individual’s cardiovascular and pulmonary efficiency, which is vital for both clinical and research purposes.
They enable healthcare professionals to assess responses to exercise, identify potential health issues, and develop tailored rehabilitation programs. The technological advancements in metabolic carts have fostered improved accuracy and user-friendliness, making them indispensable in cardiopulmonary evaluations across hospitals and fitness centers in the US.
In addition to CPET Metabolic Carts, software solutions accompanying these devices have gained significant traction. This software not only enhances the functionality of the metabolic carts by processing and analyzing data efficiently but also allows for the integration of electronic health records, ensuring a seamless workflow for healthcare practitioners.
The rise in telemedicine and remote patient monitoring has also led to an increased reliance on such software, as it aids in data sharing and management. With the growing emphasis on personalized medicine and preventative health measures, these software solutions enable tailored exercise prescriptions and ongoing patient engagement, thereby driving their importance in the industry.
The US market is witnessing innovative developments in both hardware and software, which collectively enhance the quality of care provided to patients with cardiopulmonary conditions. As the focus on cardiovascular health continues to grow, the demand for advanced CPET Metabolic Carts and integrated software solutions is expected to expand, reflecting the overall trends within the US Cardiopulmonary Exercise Testing Market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Cardiopulmonary Exercise Testing Market is significantly influenced by its End User segment, which comprises Hospitals and Clinics, Diagnostic Centers, Ambulatory Centers, and Others. Hospitals and Clinics play a crucial role in delivering essential cardiopulmonary tests, driving the demand due to their comprehensive care pathways and the presence of advanced medical technology. Diagnostic Centers are vital as they provide specialized services that cater to a wide array of patients seeking precise testing, thus contributing to the overall market dynamics.
Ambulatory Centers are gaining prominence as they offer convenience and accessibility for patients, facilitating timely diagnosis and management of cardiopulmonary conditions. The Others category includes various healthcare facilities and flexible testing venues, which also contribute to the diversity of service options for patients.
The trends in this segment reflect the increasing focus on preventive healthcare, pushing for enhanced testing capabilities across all types of facilities. As healthcare continues to evolve, the US Cardiopulmonary Exercise Testing Market segmentation reveals critical insights into healthcare delivery, highlighting the importance of diverse End Users in improving patient outcomes and accessibility.
The US Cardiopulmonary Exercise Testing Market is characterized by a range of competitive dynamics shaped by various factors, including technological advancements, regulatory frameworks, and a growing emphasis on preventive healthcare. The demand for cardiopulmonary exercise testing is propelled by the increasing prevalence of respiratory and cardiovascular diseases, along with the rising awareness about the importance of exercise testing in clinical settings. This environment has led to the emergence of several key players that are continually innovating to capture market share.
Companies are engaging in strategic partnerships, mergers, and acquisitions to enhance their product offerings and improve their overall competitive positions. The landscape of this market is dynamic, driven by advancements in testing technologies and increasing applications in both clinical and sports performance settings.
CareFusion, known for its significant contributions to the medical equipment industry, maintains a strong presence in the US Cardiopulmonary Exercise Testing Market. The company has established itself as a reliable provider of respiratory and monitoring equipment, essential for conducting effective cardiopulmonary assessments. CareFusion’s strength lies in its commitment to innovation and high-quality products that meet regulatory standards. By offering a range of advanced testing solutions, the company has managed to build a loyal customer base among healthcare providers.
Their focus on integrating cutting-edge technology, which allows for enhanced monitoring and analysis, sets them apart from competitors. Additionally, CareFusion’s comprehensive training and support services further solidify its reputation in the market, enabling healthcare professionals to utilize their equipment efficiently and effectively.
Cosmed has positioned itself as a prominent player in the US Cardiopulmonary Exercise Testing Market, leveraging its expertise in cardiopulmonary diagnostics to deliver high-performance products and services. The company specializes in advanced metabolic and cardiopulmonary testing systems, which are integral to evaluating patient health and physical performance. Cosmed's strong emphasis on research and development has resulted in a portfolio that includes state-of-the-art metabolic carts and pulmonary function testing equipment.
Its presence in the US market is further enhanced by strategic partnerships and collaborations, facilitating innovation and expanding its market reach. Strengths such as a robust distribution network and responsive customer service have contributed to its competitive edge. In recent years, Cosmed's strategic mergers and acquisitions have enabled it to diversify its product offerings, solidifying its position as a leader in cardiopulmonary exercise testing solutions while responding to the evolving needs of healthcare professionals across the United States.
The US Cardiopulmonary Exercise Testing Market has seen significant developments recently, particularly with advancements in technology and regulatory approvals. Companies such as GE Healthcare and Nihon Kohden are focusing on enhancing their product offerings to provide accurate diagnostics through innovative testing solutions. In terms of market dynamics, the increasing prevalence of cardiovascular diseases is driving demand for cardiopulmonary exercise testing, leading to a rise in market valuations for companies like CareFusion and Cosmed, which reported growth due in part to expanding applications in clinical settings.
Notably, in June 2023, CardioCommand acquired MediCardia, a strategic move aimed at enhancing capabilities in cardiopulmonary diagnostics. Additionally, partnerships among firms like Huntleigh and Cleveland Medical Devices are emerging to leverage synergies and improve patient care. Over the last two years, significant investments in Research and Development have been noted, with Borg Health and KORR Medical Technologies making strides in tailored exercise testing solutions. The US market’s landscape is evolving rapidly with an emphasis on integrating advanced technology and focusing on patient-centered approaches, thus reflecting a robust growth trajectory for the industry.
| Report Attribute/Metric | Details |
| Market Size 2023 | 220.5(USD Million) |
| Market Size 2024 | 235.2(USD Million) |
| Market Size 2035 | 530.0(USD Million) |
| Compound Annual Growth Rate (CAGR) | 7.665% (2025 - 2035) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | CareFusion, Cosmed, CardioCommand, Nihon Kohden, Huntleigh, Cleveland Medical Devices, Borg Health, MediCardia, Parker Hannifin, KORR Medical Technologies, GE Healthcare, Bodystat, Schiller AG, Mediware |
| Segments Covered | Product, End User |
| Key Market Opportunities | Increased prevalence of cardiopulmonary diseases, Growing demand for personalized medicine, Advancements in wearable exercise technologies, Expansion of telehealth services, Rising awareness of fitness and wellness |
| Key Market Dynamics | Rising cardiovascular diseases, Increasing demand for early diagnosis, Advancements in testing technology, a Growing geriatric population, and Favorable reimbursement policies |
| Countries Covered | US |
Frequently Asked Questions (FAQ) :
The US Cardiopulmonary Exercise Testing Market is expected to be valued at 235.2 million USD in 2024.
By 2035, the market is projected to reach a value of 530.0 million USD.
The expected compound annual growth rate is 7.665% from 2025 to 2035.
The CPET Metabolic Carts segment is expected to dominate with a value of 140.0 million USD in 2024.
The Software segment is projected to be valued at 95.2 million USD in 2024.
The CPET Metabolic Carts segment is expected to grow to 320.0 million USD by 2035.
The Software segment is anticipated to reach a value of 210.0 million USD in 2035.
Major players include CareFusion, Cosmed, CardioCommand, and GE Healthcare, among others.
Growth drivers include the increasing prevalence of cardiovascular diseases and advancements in testing technologies.
The current global scenario has heightened the focus on health diagnostics, positively influencing market growth.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
